Results 111 to 120 of about 19,815 (203)

Novel prognostic factors in chronic myeloid leukemia [PDF]

, 2008
Chronic myeloid leukemia (CML) is a malignant clonal blood disease that originates from a pluripotent hematopoietic stem cell. The cytogenetic hallmark of CML, the Philadelphia chromosome (Ph), is formed as a result of reciprocal translocation between ...
Lundán, Tuija
core  

Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia [PDF]

, 2016
The use of tyrosine kinase inhibitors (TKI), including nilotinib, has revolutionized the treatment of chronic myeloid leukemia (CML). However current unmet clinical needs include combating activation of additional survival signaling pathways in ...
Arbiser, Arbiser, Bellamkonda, Bellamkonda, Bhatia, Bruner-Klisovic, Cao, Cao, Cao, Cao, Cao, Cao, Cao, Chandra, Chen, Dikalov, Gallo, Goris, Holyoake, Holyoake, Holyoake, Holyoake, Holyoake, Jordan, Kantarjian, Kogan, Larsson, Lehn, Li, Lozzio, Marcucci, Miyoshi, Neviani, Omay, Passegue, Passegue, Passegue, Perrotti, Rousselot, Rowntree, Shah, Skorski, Stoklosa, Suda, Tonks, White, Yang, Zhang   +47 more
core   +3 more sources

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase [PDF]

, 2015
BCR-ABL1 mutations are a common, well-characterized mechanism of resistance to imatinib as first-line treatment of chronic myeloid leukemia in chronic phase (CML-CP). Less is known about mutation development during first-line treatment with dasatinib and
A Hochhaus, A Hochhaus, E Jabbour, E Jabbour, E Jabbour, E Jabbour, FE Nicolini, FX Gruber, H de Lavallade, H Kantarjian, HA Bradeen, HM Kantarjian, HM Kantarjian, IJ Griswold, J Cortes, JE Cortes, JE Cortes, JE Cortes, JF Apperley, JS Ahn, JS Khorashad, M Baccarani, M Baccarani, M Deininger, M Talpaz, MC Müller, MC Müller, NP Shah, NP Shah, RA Larson, S Branford, S Branford, S Branford, S Redaelli, S Soverini, S Soverini, S Soverini, S Soverini, S Soverini, SG Willis, T Ernst, T Hughes, T Hughes, T Lange, T O'Hare, T O’Hare, WS Kim, WT Parker, WT Parker, X Jiang, Z Iqbal   +50 more
core   +2 more sources

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Blood, 2007
Abstract Nilotinib, an orally bioavailable, selective Bcr-Abl tyrosine kinase inhibitor, is 30-fold more potent than imatinib in pre-clinical models, and overcomes most imatinib resistant BCR-ABL mutations. In this phase 2 open-label study, 400 mg nilotinib was administered orally twice daily to 280 patients with Philadelphia chromosome ...
KANTARJIAN HM, GILES F, GATTERMANN N, BHALLA K, ALIMENA, Giuliana, PALANDRI F, OSSENKOPPELE GJ, NICOLINI FE, O'BRIEN SG, LITZOW M, BHATIA R, CERVANTES F, HAQUE A, SHOU Y, RESTA DJ, WEITZMAN A, HOCHHAUS A, LE COUTRE P.   +17 more
openaire   +4 more sources

TREATMENT WITH IMATINIB MESILAT IN CHRONIC MYELOGENOUS LEUKEMIA – OUR EXPERIENCE

Zdravniški Vestnik, 2004
Background. Chronic myelogenous leukemia (CML) is a malignant clonal disorder of hematopoietic stem cell. In majority of patients we find reciprocal chromosomal translocation t (9.22) which result in fusion oncoprotein with tyrosine kinase activity.
Mateja Grat, Joško Vučkovič
doaj  

An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture [PDF]

, 1998
IFN-alpha has been shown to prolong survival in chronic myeloid leukemia patients, but its mechanism of action is still not understood.
Borsboom, A. (Astrid), Cornelissen, J.J. (Jan), Hagemeijer, A. (Anne), Kluin-Nelemans, J.C. (Hanneke), Löwenberg, B. (Bob), Ploemacher, R.E. (Robert), Wognum, B.W.   +6 more
core   +1 more source

Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital

Revista Brasileira de Hematologia e Hemoterapia, 2013
Objetive: The aim of this study was to identify the reasons for failure in adherence to imatinib mesylate treatment in chronic myeloid leukemia. Methods: A retrospective review was performed of
Samuel Roosevelt Campos dos Reis, Acy Telles de Souza Quixada, Sammara Tavares Nunes, Danielle Maria Camelo Cid, Jacqueline Holanda de Souza, Clara Maria Bastos Eloy da Costa, Carolina Bizelli Silveira, David Antonio Camelo Cid, Mariana Fatima Cabral de Oliveira   +8 more
doaj   +1 more source

Immune effector recovery in chronic myeloid leukemia and treatment-free remission [PDF]

, 2017
Chronic myeloid leukemia (CML) is a hematological cancer, characterized by a reciprocal chromosomal translocation between chromosomes 9 and 22 [t(9;22)], producing the Bcr-Abl oncogene. Tyrosine kinase inhibitors (TKIs) represent the standard of care for
Hughes, A., Yong, A.
core   +1 more source

Myeloid sarcoma: an uncommon presentation of myeloid neoplasms; a case series of 4 rare cases reported in a tertiary care institute

Autopsy and Case Reports, 2021
Myeloid sarcoma (MS) is a rare extramedullary neoplasm of myeloid cells, which can arise before, concurrently with, or following hematolymphoid malignancies.
Toyaja Jadhav, Puneet Baveja, Arijit Sen   +2 more
doaj  

Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome

Revista Brasileira de Hematologia e Hemoterapia, 2012
OBJECTIVE: This study aimed to verify the association between human leukocyte antigens and the bcr-abl fusion protein resulting from t(9;22)(q34;q11) in chronic leukemia myeloid and acute lymphoblastic leukemia patients.
Daiana Landenberger de Carvalho, Cristian Dias Barbosa, André Luiz de Carvalho, Sandra Trevisan Beck   +3 more
doaj   +1 more source